Company Overview and News
Stocks started and finished the day in the black on Thursday, but did so without the help of several of the usual suspects. Netflix (NASDAQ:NFLX) ended the day down a bit, while Advanced Micro Devices (NASDAQ:AMD) tumbled 5.4% for no clear reason … other than the possibility that the sheer weight of its recent gains is starting spook newcomers.
LMT MU CMCSA AAPL PPL AMD NFLX
A little late with this post as I like to highlight my potential stock buys in the beginning of the month but sometimes it can be tough deciding where to deploy fresh capital when many stocks are trading at premium prices. Of course, we all know that no matter how high the market rises, there will always be a gem in the rough lurking somewhere. With that being said, let's take a look at some of my September stock considerations.
D HCP PPL SBRA SBRAP
2018-09-05 investorplace - 1
U.S. equities stumbled out of the gate on Wednesday, continuing their recent bout of weakness as a number of high-beta large-cap technology stocks suffered a round of selling pressure. Stocks in the periphery of the “FAANGs” such as semiconductor and cloud computing names also rolled over.
SOJA SO FB F TWTR PPL CTL MO
The company offers a high dividend that will grow at a rate that easily beats inflation.
2018-08-21 seekingalpha - 1
This is the fifth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $1,610.61.
GIS WBA ENB OPRF WMB SCHF JCI HSY ABBV MMM POL MO DUKH GD BAC TRV GILD MAIN CMI ENB RY BNS JNJ ITW VZ WPC ABBV MSFT ADM PFE PM PFBC IRET CTL OXLCM OXLCO TD ETN OXLCN BNS BAC MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF AFL ORI PPL
2018-08-19 seekingalpha - 1
"The S&P 500 is widely-regarded as the best single gauge of large-cap U.S. equities. The index includes 500 leading companies and captures approximately 80% coverage of available market capitalization."---us.spindices.com.
VTR PM XOM NLSN LB KMI KHC WMB PPL WELL GM KMR CVB KMRFZ IVZ COTY
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to PPL / PPL Corp. on message board site Silicon Investor.
as of ET